首页> 外文期刊>In Vitro Cellular and Developmental Biology. Animal: Journal of the Tissues Culture Association >Purification of serine protease from polychaeta, Lumbrineris nipponica, and assessment of its fibrinolytic activity
【24h】

Purification of serine protease from polychaeta, Lumbrineris nipponica, and assessment of its fibrinolytic activity

机译:从多芯片,Lumbrineris nipponica纯化丝氨酸蛋白酶,评估其纤维蛋白溶解活性

获取原文
获取原文并翻译 | 示例
           

摘要

Ischemic stroke and cardiovascular disease can occur from blockage of blood vessels by fibrin clots formed naturally in the body. Therapeutic drugs of anticoagulant or thrombolytic agents have been studied; however, various problems have been reported such as side effects and low efficacy. Thus, development of new candidates that are more effective and safe is necessary. The objective of this study is to evaluate fibrinolytic activity, anti-coagulation, and characterization of serine protease purified from Lumbrineris nipponica, polychaeta, for new thrombolytic agents. In the present study, we isolated and identified a new fibrinolytic serine protease from L. nipponica. The N-terminal sequence of the identified serine protease was EAMMDLADQLEQSLN, which is not homologous with any known serine protease. The size of the purified serine protease was 28 kDa, and the protein purification yield was 12.7%. The optimal enzyme activity was observed at 50A degrees C and pH 2.0. A fibrin plate assay confirmed that indirect fibrinolytic activity of the purified serine protease was higher than that of urokinase-PA, whereas direct fibrinolytic activity, which causes bleeding side effects, was relatively low. The serine protease did not induce any cytotoxicity toward the endothelial cell line. In addition, anticoagulant activity was verified by an in vivo DVT animal model system. These results suggest that serine protease purified from L. nipponica has the potential to be an alternative fibrinolytic agent for the treatment of thrombosis and use in various biomedical applications.
机译:通过在体内自然形成的纤维蛋白凝块可以从血管堵塞发生缺血性卒中和心血管疾病。研究了抗凝血剂或溶栓剂的治疗药物;然而,报告了各种问题,例如副作用和低功效。因此,需要开发更有效和安全的新候选人。本研究的目的是评估从Lumbrineris nipponica,Polychaeta纯化的纤维蛋白溶解活性,抗凝固和表征,用于新的溶栓剂。在本研究中,我们分离并鉴定了来自L. nipponica的新纤维蛋白溶解丝氨酸蛋白酶。鉴定的丝氨酸蛋白酶的N-末端序列是EAMMDLADQLEQSLN,其与任何已知的丝氨酸蛋白酶不同源。纯化的丝氨酸蛋白酶的尺寸为28kDa,蛋白质纯化收率为12.7%。在50A℃和pH 2.0处观察到最佳酶活性。纤维蛋白板测定证实纯化的丝氨酸蛋白酶的间接纤维蛋白溶解活性高于尿激素-Pa的纤维蛋白溶解活性,而导致副作用的直接纤维蛋白溶解活性相对较低。丝氨酸蛋白酶没有诱导内皮细胞系的任何细胞毒性。此外,通过体内DVT动物模型系统验证了抗凝血活性。这些结果表明,从L.Nipponica纯化的丝氨酸蛋白酶具有替代纤维蛋白溶解剂,用于治疗血栓形成和在各种生物医学应用中使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号